ClinicalTrials.gg
Status unknownNCT01603030Updated May 22, 2012

Efficacy of Moxifloxacin/Prednisolone in Prevention of Post Surgery Inflammation

A Phase 3 interventional study of moxifloxacin 0,5% + prednisolone 1% and moxifloxacin/prednisolone combination in Eye Infection/Inflammation Other, sponsored by Adapt Produtos Oftalmológicos Ltda.. Status unknown at 1 site in Brazil. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2012-05-22.

Sponsored by Adapt Produtos Oftalmológicos Ltda. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2012), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a Unicentric, double-blind, randomized, two-arm, parallel-group study to demonstrate the efficacy of moxifloxacin/prednisolone acetate fixed combination compared with individual administration of moxifloxacin + acetate Prednisolone Eye drops in Prevention of Post Operative Inflammation and Infection in LASIK surgery.

Read the detailed description

antibiotic/steroid combination compared to individuals components 15 days of treatment

02

Conditions studied

  • Eye Infection/Inflammation Other

Browse trials for

Keywords

  • Moxifloxacin
  • Prednisolone
  • LASIK
03

In context

Eye Infections

31 studies on the registry are indexed under Eye Infections; 4 are open to participants now.

This study's planned enrollment of 66 is below the median of 109 across 24 interventional studies indexed under Eye Infections.

Browse Eye Infections studies →

Lead sponsor

Adapt Produtos Oftalmológicos Ltda. is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women of any race, between 18 and 50 years of age up to 8 degrees of myopia or hyperopia of up to 04 degrees or up to 3 degrees without astigmatism and other eye problems associated.
  • Able to understand and provide ,
  • Willingness to complete all required study visits,
  • Willingness to undergo surgery to correct grade (myopia, astigmatism, hyperopia) by LASIK in both eyes (at the same surgical or surgical procedures separated) or in only one eye.
  • Examination of normal fundus by direct ophthalmoscopy or indirect;
  • Measurements of intraocular pressure (IOP), treated or untreated, less than or equal to 20 mmHg. Individuals with glaucoma / ocular hypertension are eligible if their blood pressure is controlled by a single ocular hypotensive agent with the exception noted in criterion of exclusion. 16.
  • Women who may become pregnant (those that are not surgically sterile or ) may participate in the study if they meet all the following conditions: a)not breastfeeding; b)have a negative pregnancy test at screening prior to recruitment; c)agree to submit to a urine test for pregnancy at the time of its withdrawal from the study; d)not to conceive during the study period; e)are using methods appropriate and agrees to continue to use birth control methods appropriate for the duration of the study (the methods of birth control are adequate: hormonal contraceptives - oral, implantable or injectable; mechanics - spermicide associated with a barrier method like a condom or diaphragm, IUD, or sterilization of the partner).

Exclusion criteria

Exclusion Criteria:

  • Glaucoma or intraocular hypertension not controlled;
  • Use of nonsteroidal antiinflammatory drugs (NSAIDs) ocular topical or systemic drugs (NSAIDs) during the study and the 14 days prior to study entry, except for an allowed daily dose of aspirin low-dose (100 mg);
  • Ocular anti-infective drug use during the study and within 30 days prior to study entry or any other eye medicines with the exception noted in criterion Insertion 6.
  • Topical , inhaled or systemic ocular during the study and the 14 days prior to study entry;
  • Ocular trauma in the eye prior to operate (including intraocular surgery in the previous twelve months due to trauma or cataract in the past);
  • History of chronic ocular inflammatory disease or recurrent (ie, iritis, scleritis, uveitis, iridocyclitis, rubeosis iridis) in the eye to be operated;
  • Any intraocular inflammation (score of cells than Grade 0) to be present during the examination of slit lamp or ocular pain increased in the Grade 1 -2 Day in the study eye (eye operation);
  • Proliferative diabetic retinopathy (eye operation) non-proliferative diabetic retinopathy, moderate to severe (eye operation);
  • Uncontrolled diabetes mellitus;
  • Patients with vision in one eye or vision not correctable to LogMAR 1.0 or better in each eye using the ETDRS framework;
  • Participation in any other clinical study within 12 months prior to surgery, pregnant women, lactating or under conditions of breeding methods that are not using adequate (as defined in the criteria for inclusion, above);
  • Known or suspected allergy or to moxifloxacin, steroids, topical anesthetics or any other component of the study medication;
  • History or other evidence of severe illness, or other systemic conditions that may cause the patient, in the opinion of the Investigator, the study is inadequate;
  • Patients with epithelial herpes simplex (dendritic keratitis), vaccinia, varicella, or other viral disease of the cornea or conjunctiva, tuberculosis of the eye, fungal diseases of ocular structures;
  • Patients who use a topical ophthalmic prostaglandin, such as ,Travatan® (travoprost),Xalatan®(latanoprost),Lumigan®(bimatoprost)and Rescula®(unoprostone) should discontinue their use starting four days before surgery until their departure from study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    moxifloxacin/prednisolone combination

    1 gtt, 4x/day, 15 days

    Drug: moxifloxacin/prednisolone combination

  • Active comparator
    moxifloxacin 0,5% + Prednisolone 1%

    1 drop of each bottle, BID, 15 days

    Drug: moxifloxacin 0,5% + prednisolone 1%

Interventions

  • Drugmoxifloxacin 0,5% + prednisolone 1%

    1 gtt, 4x/day, 15 days

    Also known as: moxifloxacin 0,5%, prednisolone 1%

  • Drugmoxifloxacin/prednisolone combination

    Drug pages: Moxifloxacin · Prednisolone

    1 gtt, 4x/day, 15 days

    Also known as: moxifloxacin 0,5%; predfort

06

What researchers measure

Primary outcomes

  1. Day 15 Evaluation of Anterior Chamber

    The primary efficacy variable of this study is the percentage of patients with a score of zero postoperative inflammation (anterior chamber inflammation, ie, presence of cells in the anterior chamber (0-4) in the study on Day 15. The absence of bacterial infection on Day 15 ± 1 will be assumed to demonstrate that the antibacterial agents in the association of moxifloxacin / acetate Prednisolona1% and moxifloxacin + acetate Prednisolona1% Eye drops are equal in antimicrobial effectiveness, and that they acted in a prophylactic manner to prevent of bacterial infection.

    Time frame: 15 days

Secondary outcomes

  1. day 15 physician´s follow-up impression of inflammatory reaction score

    the clinical evaluation will be based on the following variables: IOP, assessment of visual acuity, slit lamp examination (lids, conjunctiva, cornea), and examination of the fundus (retina / macula / choroid, vitreous and optic nerve).

    Time frame: 15 days

07

Study locations

1 site
  • Universidade Federal de São Paulo - Hospital São Paulo - UNIFESP
    São Paulo, SP/Brazil 4562-020, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Aug 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2011
First posted
May 22, 2012
Start
Jun 2012
Primary completionEst.
Aug 2012
CompletionEst.
Sep 2012
Last update
May 22, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01603030
Lead sponsor
Adapt Produtos Oftalmológicos Ltda.
Responsible party
Sponsor
First posted
May 22, 2012
Start date
Jun 2012
Primary completion
Aug 2012 (estimated)
Completion
Sep 2012 (estimated)
Last update
May 22, 2012

Study contacts

Rubens Belfort, investigator
Contact
prof.belfort@clinicabelfort.com.br
5511 5572-6443
Cristina Mucioli, coordinator
Contact
crissmucci@gmail.com
55115572-6443
Cristina Mucioli, Dra.
study chair · Universidade Federal de São Paulo - Hospital São Paulo - UNIFESP

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Moxifloxacin · Prednisolone

Start the discussion